- HK$523.17m
- -HK$329.72m
- CNY67.31m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.49 | ||
Price to Tang. Book | 0.49 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 8.73 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -41.72% | ||
Return on Equity | -43.05% | ||
Operating Margin | -942.86% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | n/a | n/a | 28.77 | 160.13 | 67.31 | 119.1 | 271.04 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Directors
- Jay Mei CHM (54)
- Donald Lung CFO (38)
- John Chin EDR (54)
- Kevin Lynch EDR
- Kan Chen NED (39)
- Liu Yilun NED (35)
- Mark Alles NID (61)
- Jing Qian NID (44)
- Sheng Tang NID (37)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 28th, 2018
- Public Since
- November 20th, 2020
- No. of Employees
- 178
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 679,446,632

- Address
- Ugland House, SHANGHAI, KY1-1104
- Web
- https://www.antengene.com/
- Phone
- Auditors
- Ernst & Young CPA
Upcoming Events for 6996
Antengene Corporation Ltd Annual Shareholders Meeting
Similar to 6996
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
Beigene
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 18:17 UTC, shares in Antengene are trading at HK$0.77. This share price information is delayed by 15 minutes.
Shares in Antengene last closed at HK$0.77 and the price had moved by -36.89% over the past 365 days. In terms of relative price strength the Antengene share price has underperformed the FTSE Developed Asia Pacific Index by -36.58% over the past year.
The overall consensus recommendation for Antengene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAntengene does not currently pay a dividend.
Antengene does not currently pay a dividend.
Antengene does not currently pay a dividend.
To buy shares in Antengene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.77, shares in Antengene had a market capitalisation of HK$523.17m.
Here are the trading details for Antengene:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6996
Based on an overall assessment of its quality, value and momentum Antengene is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Antengene is HK$1.33. That is 72.46% above the last closing price of HK$0.77.
Analysts covering Antengene currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.67 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Antengene. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +32.26%.
As of the last closing price of HK$0.77, shares in Antengene were trading +1.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Antengene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Antengene's management team is headed by:
- Jay Mei - CHM
- Donald Lung - CFO
- John Chin - EDR
- Kevin Lynch - EDR
- Kan Chen - NED
- Liu Yilun - NED
- Mark Alles - NID
- Jing Qian - NID
- Sheng Tang - NID